See more : Ubon Bio Ethanol Public Company Limited (UBE.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Vincerx Pharma, Inc. (VINC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vincerx Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- i3 Verticals, Inc. (IIIV) Income Statement Analysis – Financial Results
- Dongfeng Motor Group Company Limited (DNFGF) Income Statement Analysis – Financial Results
- Beijing North Star Company Limited (0588.HK) Income Statement Analysis – Financial Results
- Church & Dwight Co., Inc. (0R13.L) Income Statement Analysis – Financial Results
- Mr D.I.Y. Group (M) Berhad (MDIYF) Income Statement Analysis – Financial Results
Vincerx Pharma, Inc. (VINC)
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 915.00K | 939.00K | 340.00K | 173.00K | 173.00K |
| Gross Profit | -915.00K | -939.00K | -340.00K | -173.00K | -173.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 28.97M | 52.15M | 40.08M | 7.12M | 0.00 |
| General & Administrative | 13.64M | 18.95M | 22.58M | 3.60M | 54.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 44.95K |
| SG&A | 13.64M | 18.95M | 22.58M | 3.60M | 45.00K |
| Other Expenses | 0.00 | 1.24M | -8.00K | -8.00K | 0.00 |
| Operating Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Cost & Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Interest Income | 1.25M | 664.00K | 0.00 | 54.27K | 54.27K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 |
| Depreciation & Amortization | 52.00K | 939.00K | 340.00K | 5.71M | 54.00K |
| EBITDA | -42.61M | -68.67M | -62.66M | -10.71M | 9.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.61M | -73.57M | -62.66M | -10.71M | -45.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.45M | 8.21M | 23.35M | -5.91M | 0.00 |
| Income Before Tax | -40.16M | -65.37M | -39.31M | -10.72M | -45.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.21M | -23.70M | 8.00K | -54.00 |
| Net Income | -40.16M | -57.16M | -15.61M | -10.73M | -45.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| EPS Diluted | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| Weighted Avg Shares Out | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
| Weighted Avg Shares Out (Dil) | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update
Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome
Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
Vincera Pharma Announces Name Change to Vincerx
Source: https://incomestatements.info
Category: Stock Reports